TYVASO DPI IS NOW APPROVED

BENEFITS OF REACHING TARGET DOSE

Help your patients get the most out of TYVASO by achieving the target maintenance dose1

6MWD

Patients receiving a higher dose of TYVASO achieved a 67% greater improvement in 6MWD at 16 weeks1

Patients receiving a higher dose of TYVASO achieved nearly double the improvement in 6MWD at 16 weeksPatients receiving a higher dose of TYVASO achieved nearly double the improvement in 6MWD at 16 weeks

Hodges-Lehmann placebo-corrected median difference.

In the MMRM analysis, patients achieving 10-12 breaths had nearly double the improvement in 6MWD at 16 weeks. Change in 6MWD by dose was a prespecified subgroup analysis.2

Clinical Worsening

Fewer patients in the higher-dose group experienced a clinical worsening event3

The clinical worsening data is a post hoc analysis of data from a prespecified efficacy endpoint.The clinical worsening data is a post hoc analysis of data from a prespecified efficacy endpoint.

Percentage of patients experiencing an event.

The clinical worsening data is a post hoc analysis of data from a prespecified efficacy endpoint. Interpret with appropriate caution.

Our TYVASO Nebulizer Treatment Tracker can help your patients stay on track with their treatment sessions.

Setting your patients up for success

1

Set realistic expectations

  • As the patient titrates to target maintenance dose, they may not see immediate clinical improvements4

2

Prepare for common AEs

  • Review AEs (eg, cough, headache, and throat irritation) and why they may occur5
  • Give patients specific instructions to proactively manage any AEs that occur
  • Complete AE Management section on the Referral Form

3

Ensure patients understand the dosing plan

  • With the TYVASO nebulizer, target maintenance dose can be achieved by starting with 3 breaths per session at week 1 and increasing by 1 breath per week until reaching 9-12 breaths per session1,6
  • With TYVASO DPI, target maintenance dose can be achieved by starting with 16 mcg (1 cartridge) and increasing by 16 mcg at 1- to 2-week intervals to a target maintenance dose of 48 mcg to 64 mcg per treatment session7
  • Once the target maintenance dose is achieved, the patient should maintain that dose with each treatment session, as tolerated

6MWD=6-minute walk distance; AE=adverse event; MMRM=mixed-effect model repeat measurement.

TYVASO DPI
THE PROVEN EFFICACY OF TYVASO® IN THE PALM OF YOUR HAND1,2

TYVASO DPI Inhalation Powder is a simple-to-use, inhaled prostacyclin therapy that delivers the trusted safety and benefits of TYVASO.1,2

Get the details about TYVASO DPI.

DPI=dry powder inhaler.

References: 1. TYVASO DPI [package insert]. Research Triangle Park, NC: United Therapeutics Corporation; 2022. 2. Spikes LA, Bajwa AA, Burger CD, et al. BREEZE: open-label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI in patients with pulmonary arterial hypertension. Pulm Circ. 2022;12:e12063. doi:10.1002/pul2.12063.

This referral form has recently been revised to include TYVASO DPI™ (treprostinil) Inhalation Powder, a new dry powder inhaler option for your patients.

Currently, the 48 mcg (112 ct) and 64 mcg (112 ct) Maintenance Kits (28-day supply) are available for ordering. These strengths correspond with 8-10 breaths and 11-12 breaths with the TYVASO nebulizer, respectively. The remaining Maintenance Kits and Titration Kits will be available soon.

To learn more about TYVASO DPI and Kit availability, please reach out to your local United Therapeutics Cardiopulmonary Specialist.

Okay